A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...

Editas Medicine Inc (EDIT) stock saw a modest uptick, ending the day at $1.22 which represents a slight increase of $0.08 or 7.02% from the prior close of $1.14. The stock opened at $1.2 and touched a ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...

Editas Medicine ( (EDIT) ) has provided an announcement. Editas Medicine announced new in vivo preclinical proof of concept data and outlined its strategic priorities and key milestones for 2025, ...

Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Editas Medicine (EDIT – Research Report) yesterday and set a ...

Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $1.16 which represents a decrease of $-0.10 or -7.94% from the prior close of $1.26. The stock opened at $1.24 and touched a low of $1 ...

It has been about a month since the last earnings report for Editas Medicine (EDIT). Shares have lost about 36.5% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Editas Medicine reports preclinical success in gene editing for sickle cell disease and beta thalassemia, with strategic milestones for 2025. Editas Medicine, Inc. announced significant ...

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR ...

Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. The firm’s revenue was down 98.9% on a year-over-year basis. During the same period in the prior ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...